This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) to decide which new medicines to recommend for use in the NHS, and the direction of future research in this  area.

The study, written by OHE’s Sarah Karlsberg Schaffer, Patricia Cubi-Molla, Nancy Devlin and Adrian Towse, and commissioned by the Association of the British Pharmaceutical Industry (ABPI), involved individual interviews and a day-long workshop with 15 academic experts.